Welcome to our dedicated page for Aesthetic Medical International Holdings Group SEC filings (Ticker: PAIYY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Aesthetic Medical International Holdings Group's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Aesthetic Medical International Holdings Group's regulatory disclosures and financial reporting.
Aesthetic Medical International Holdings Group Limited filed its 2025 annual report as a Cayman Islands holding company with operating subsidiaries in mainland China and Hong Kong. Operations and cash flows depend on PRC subsidiaries, which face dividend and capital transfer restrictions under Chinese regulation.
The report highlights use of contractual arrangements to control certain PRC subsidiaries because of foreign ownership limits in medical institutions, noting legal uncertainty and potential enforcement risk in China. It also discusses HFCAA-related audit inspection risk, extensive PRC regulatory oversight of aesthetic medical services, and rising compliance, advertising and data-privacy obligations.
Aesthetic Medical International Holdings Group Ltd’s major investors have updated their ownership disclosure in Amendment No. 3 to a Schedule 13D. MY Universe (HK) Limited and affiliated entities report beneficial ownership of 36,402,570 ordinary shares, representing 23.7% of the company’s ordinary share capital.
Suqian Beibao Culture Communication Co., Ltd. and Suqian Baibao Technology Co., Ltd. are tied to this same 23.7% stake through My Universe. Individually, ZHENG Qingying and WU Guiqian each report shared beneficial ownership of 57,815,846 ordinary shares, or 37.6% of the class, through interests in My Universe and Hawyu (HK) Limited.
The filing also details a series of historic agreements, including a 36,402,570-share subscription and a 21,321,962-share purchase, and describes recent Subscription and Partnership Withdrawal Agreements that reshaped the partner structure of Jiechuang. Several entities will cease to be reporting persons, while the remaining investors state they will continue to review their investment and potential strategic alternatives.